|Bid||13.30 x 1200|
|Ask||13.71 x 800|
|Day's Range||13.41 - 14.43|
|52 Week Range||8.40 - 30.37|
|Beta (5Y Monthly)||2.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 05, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.75|
DURHAM, N.C., Nov. 15, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced the appointment of Dr. Ed Baracchini as chairman of the Company’s board of directors. “As a member of the CoImmune board of directors, Dr. Baracchini has provided strong counsel and guidance on many important issues in corporate development and strategy,” stated Dr. Charles Nicolette, chief exec
If you want to know who really controls INmune Bio, Inc. ( NASDAQ:INMB ), then you'll have to look at the makeup of its...
Image source: The Motley Fool. INmune Bio, Inc. (NASDAQ: INMB)Q3 2021 Earnings CallNov 03, 2021, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGreetings, and welcome to the INmune Bio third quarter 2021 earnings call.